KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
ALPHARETTA, Ga., Jan. 05, 2017 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that Daniel H. White, Chief Executive Officer and President of Clearside, will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2017 at 7:30am PST, at the Westin St. Francis Hotel, in San Francisco, California.
The presentation will be webcast live and may be accessed by visiting Clearside’s website at http://ir.clearsidebio.com. A replay of the webcast will be available for 30 business days.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly traded, ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and pre-clinical candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com.
Contacts Company: Charles Deignan Chief Financial Officer 678-270-4005 [email protected] Investors: Matthew Beck The Trout Group 646-378-2933 [email protected]
